FY2025 EPS Estimates for Repligen Lowered by William Blair

Repligen Co. (NASDAQ:RGEN) – William Blair reduced their FY2025 earnings per share estimates for Repligen in a note issued to investors on Wednesday, December 11th. William Blair analyst M. Larew now expects that the biotechnology company will earn $1.79 per share for the year, down from their previous estimate of $2.16. The consensus estimate for Repligen’s current full-year earnings is $1.54 per share.

A number of other research firms also recently weighed in on RGEN. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday. They issued a “hold” rating and a $165.00 price target for the company. Finally, Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Price Performance

Shares of Repligen stock opened at $158.14 on Monday. The company has a 50-day simple moving average of $143.15 and a two-hundred day simple moving average of $141.68. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The stock has a market capitalization of $8.86 billion, a price-to-earnings ratio of -427.41, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the firm posted $0.23 EPS. The company’s revenue for the quarter was up 9.7% on a year-over-year basis.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently modified their holdings of the stock. Andra AP fonden acquired a new stake in shares of Repligen during the 2nd quarter valued at $25,000. International Assets Investment Management LLC bought a new position in Repligen in the second quarter valued at about $33,000. UMB Bank n.a. grew its holdings in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the period. Finally, Resources Management Corp CT ADV bought a new position in Repligen in the 3rd quarter valued at approximately $37,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.